Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Zenith Epigenetics

Zenith Epigenetics Ltd. is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies.

  • Date:Tuesday, February 12
  • Time:2:30 PM - 2:45 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:22467
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:New epigenetic therapies for cancer
  • Company Website:https://www.zenithepigenetics.com/
  • Company HQ City:Calgary
  • Company HQ State:Alberta
  • Company HQ Country:Canada
  • Total Amount Raised to Date, in All Rounds:US$48 million
  • CEO/Top Company Official:Donald McCaffrey
  • Year Founded:2013
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:ZEN 3964
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:Zenith Epigenetics is a clinical stage biotechnology company with a broad and deep drug discovery platform in epigenetics, developing orally active, small molecules that are selective for inhibition of BET bromodomains. This platform integrates structural biology, modeling, medicinal chemistry with biochemical and cell-based assays to discover potent compounds which are then further evaluated for desirable pharmaceutical properties, including oral bioavailability, and in animal models of disease. Through ongoing discovery activities we are continuing to secure intellectual property around novel compounds and their analogs. Our lead product, a pan selective BET inhibitor, is in clinical development for treatment of solid tumors, including prostate cancer.
Speakers
Donald McCaffrey
Zenith Epigenetics
Back